Redefine Surgery Builds AI Around Surgical Judgment

Redefine Surgery is building surgical intelligence for the part of the operating room that software still struggles to see. Founded in 2023 in Edison, New Jersey, the company is developing a portable platform that combines computer vision, artificial intelligence, data capture, and robotics for orthopedic procedures.

The founders are CEO Peter Verrillo, COO Ignacio Tzoumas, and CTO Stephen Potter. Their premise is deliberately narrower than autonomous surgery and more ambitious than a single navigation feature: technology should understand the procedure while the surgeon remains in control.

That distinction matters. Open surgery is rich with visual and operational context, but much of that context is difficult for software to capture. Anatomy changes as the procedure unfolds. Tools move through open space. Judgment is spread across exposure, alignment, implant position, and the choreography around the table. Redefine Surgery wants to make that environment legible without forcing clinicians into a rigid robotic workflow.

About Redefine Surgery

Redefine Surgery describes its approach as Collaborative Surgical Intelligence. The platform is being designed as an open, portable layer that can adapt across anatomy, instruments, and surgical workflows, beginning in orthopedics.

Its Redefine Vision System uses computer vision for trackerless navigation. Traditional navigation systems can depend on fixed arrays, fiducials, or other physical markers. Redefine Surgery's stated goal is to register anatomy visually, guide the surgeon through key steps, and capture procedural data without turning the technology into the center of the operation.

The company reports registration in seconds during early laboratory work and approximately 1 mm / 1 degree accuracy in key steps. Those are company-reported development metrics, not independently validated clinical outcomes. The platform remains under development, is not commercially available, and has not been cleared by the FDA.

The Product Is a Data System, Not Just a Camera

Visual navigation is the visible wedge. The larger product thesis is a feedback system for surgery.

Redefine Surgery wants to connect preoperative planning, intraoperative guidance, workflow analysis, and procedural data capture. Over time, that data could support more useful assistance because the system would be learning from the sequence of a procedure rather than a single static checkpoint.

This is also why the company's emphasis on surgeon control matters. A system that observes more of the operation carries more responsibility. It has to fit clinical practice, preserve data ownership, explain its guidance, and improve without asking the surgeon to surrender the judgment that makes the procedure safe.

The company says it is capturing procedures across multiple surgical specialties to train and validate proprietary AI models. It also reports working with more than 25 surgeon advisors. Both are signals of access to clinical feedback, but neither substitutes for formal validation.

A Team Built Around Surgery, Operations, and Software

The three founders bring different operating lenses to the same problem.

Verrillo's published background is in orthopedic devices and surgical technology. Tzoumas brings finance, strategy, and company operations. Potter's experience spans software, cloud systems, mobile products, and robotics.

That combination maps cleanly to the work ahead. Surgical AI companies have to build reliable software, navigate regulated product development, integrate with device partners, and prove that the economics work for hospitals. None of those disciplines can carry the company alone.

The team's public materials also reveal a useful cultural choice: the surgeon is framed as a collaborator, not a reluctant end user. Redefine Surgery says it builds through continuous clinical feedback and intends for clinicians to retain control of their data. The credibility of that promise will depend on the eventual product and contracts, but it is the right design question to surface early.

Shoulder Arthroplasty Is the First Partner Workflow

Catalyst OrthoScience became Redefine Surgery's founding partner for shoulder arthroplasty in September 2026.

The planned integration connects Catalyst's preoperative planning and implant workflow with Redefine Surgery's visual guidance, data capture, workflow optimization, and future assistive applications. It gives Redefine Surgery a defined procedure and device ecosystem in which to test whether a portable intelligence layer can improve the full workflow.

The companies describe targets of up to 4x better procedure-time efficiency and 10x lower technology cost. Those figures are goals, not demonstrated outcomes. The important signal today is not the multiple. It is the structure of the partnership: a surgical-intelligence company working inside a specific clinical and commercial workflow rather than building a generic robotics platform in isolation.

Funding With Surgeons on the Cap Table

Redefine Surgery announced an oversubscribed Pre-Seed close in September 2026. The company said the financing brought total capital raised to $10M, but it did not disclose the size of the current close, a lead investor, or a complete investor list.

The capital was described as coming predominantly from surgeon investors. That is strategically relevant. Surgeons can provide product judgment, workflow access, and peer credibility that a conventional financial backer cannot. They can also carry their own bias as stakeholders, so validation still has to stand on evidence beyond the investor network.

The company has also participated in the MassRobotics Accelerator and identifies Techstars Boston in its ecosystem. Those programs expand the technical and commercialization network around the founders, but the next milestones will be product-specific: regulatory strategy, repeatable performance, integration, and real-world workflow evidence.

Why Redefine Surgery Matters Now

Surgical robotics is often narrated as a march toward more automation. Redefine Surgery is making a more practical bet. The near-term opportunity may be better perception, better data, and better assistance around the surgeon rather than a machine designed to replace the surgeon's role.

That approach could lower the physical and economic burden of bringing intelligence into more operating rooms. It could also make surgical data more useful across planning, execution, and review. But portability is not the same as simplicity. The company still has to prove that its system can perform reliably across patients, rooms, instruments, clinicians, and edge cases.

No current public careers page or active opening was found during this research pass. The more useful growth signal is the company's expanding clinical network and its first named device partnership.

Redefine Surgery has assembled the ingredients of a serious surgical-technology company: domain experience, software depth, surgeon participation, capital, and a concrete partner workflow. Now it has to turn them into regulated evidence and repeatable clinical value.

If it succeeds, the operating room does not become autonomous. It becomes more observable, more measurable, and more capable of learning while the surgeon stays in command.